NEW YORK, Oct. 28 (GenomeWeb News) - Genome Express will collaborate with France's Centre Léon Bérard in Lyon and the Centre Jean Perrin in Clermont Ferrand on the Mutacancer research program, the company said today.
Under the agreement, the Léon Bérard and the Jean Perrin centers gains access to the French company's technology and will keep the discoveries from the project. Genome Express will own any advances in screening technology.
Mutacancer, a sequencing program for mutational analysis of 300 gene candidates in human cancers, identifies diagnostic and therapeutic targets. The cancer diagnostics and therapeutics program targets breast, colon, and lung cancers.
Research results will be accessible to others in the healthcare sector, the partners said. They will consider offering joint services to the pharmaceutical industry.